NAD+ heart health, traced through the research literature

The short version

This page covers NAD+ heart health research — the cardiometabolic studies dealt to this site. In plain terms: researchers gave the NAD+ precursors (the building blocks NR and NMN) to people and to animals, then measured heart and blood-vessel outcomes. NAD+ (the energy-handling helper molecule introduced on the home page) declines in failing and aging hearts, which is the rationale they were testing. In people, oral NR roughly doubled blood NAD+ in heart-failure patients and lowered systolic blood pressure in adults with elevated readings. In mice, NMN prevented a model of heart failure outright. None of this is an approved treatment, and the human work is small and early. Each step below is tied to its study, with the honest gaps flagged.

Step one: the human heart-failure signal

The most direct human cardiac evidence comes from heart failure with reduced ejection fraction (HFrEF). In a safety-and-tolerability study, oral NR at 1000 mg twice daily for 21 days was well tolerated in HFrEF patients and roughly doubled whole-blood NAD+, while reducing pro-inflammatory cytokine production in peripheral blood mononuclear cells ^[6]. That is a clean intervention-to-outcome step: NR 1000 mg BID → blood NAD+ ~2× → lower PBMC inflammatory signaling.

What the study did not do is equally important. It was a safety and biomarker trial, not an outcomes trial — it did not show that NR improves survival, ejection fraction, or symptoms over the long run ^[6]. The signal is mechanistic and promising; it is not proof of clinical benefit.

Step two: blood pressure and arterial stiffness

In healthy middle-aged and older adults with above-normal baseline blood pressure, NR at 500 mg twice daily (1000 mg/day) for six weeks significantly reduced systolic blood pressure and arterial stiffness, with the effect concentrated in participants whose baseline pressure was elevated ^[10]. The trial confirmed safety and tolerability at that dose ^[10]. Arterial stiffness — how rigid the large arteries have become — is itself a recognized cardiovascular risk marker, so a measured reduction is meaningful rather than cosmetic.

This is one of the more encouraging cardiometabolic readouts in the field because it touches a hard cardiovascular risk factor rather than only a blood biomarker. The pattern that the benefit clustered in people who started with elevated pressure is worth noting: it hints that NR may move a risk marker mainly where there is room to move it. Still, it is a single mechanistic trial in a select group, and it measures a surrogate (blood pressure, stiffness), not cardiovascular events like strokes or heart attacks.

Step three: the rodent heart-failure and diabetes models

The animal data are where the effect sizes are largest. In mice, NMN at 500 mg/kg/day by intraperitoneal injection prevented pressure-overload-induced heart failure, preserving left-ventricular contractile function and mitochondrial ultrastructure, reducing reactive oxygen species, and achieving 100% survival at five days post-surgery versus high mortality in untreated controls ^[8]. The finding was validated in neonatal rat ventricular myocytes ^[8].

On the metabolic side, NMN restored compromised NAD+ biosynthesis in metabolic organs of diet- and age-induced diabetic mice, ameliorated glucose intolerance, and enhanced hepatic insulin sensitivity partly through SIRT1 activation ^[7]. These rodent results are dramatic — and they are the reason for the caution the next section raises about extrapolating to humans.

Caution: where the heart-health evidence stops

Three honest gaps sit on this lens. First, the strongest cardiac results — full prevention of heart failure, 100% survival — are from mice given injected NMN at 500 mg/kg/day, a dose and route that do not translate directly to oral human supplementation ^[8]. Second, the human cardiovascular trials are small, short, and measure biomarkers and surrogates (blood NAD+, blood pressure, arterial stiffness), not events like heart attacks or mortality ^[6][10]. Third, a 2025 Nature Metabolism review concluded that human efficacy for hard clinical endpoints across NAD+ precursor research remains preliminary ^[15].

Separately, injectable and IV NAD+ marketed in wellness settings is compounded, not FDA-approved, and a compounded NAD+ injection has been subject to a Class I recall for elevated bacterial endotoxin — a documented quality risk, not an approved cardiac therapy.

What is an NAD injection?

An injectable or intravenous form of NAD+ given in wellness or clinic settings. It is compounded, not FDA-approved, and a compounded NAD+ injection has been recalled (Class I) for endotoxin contamination. Pilot data show infused NAD+ is rapidly cleared from plasma, with near-complete removal within the first hours ^[15].

Is NAD+ shot worth it?

Controlled evidence for injectable or IV NAD+ is the weakest in the field, limited to small pilot and retrospective reports, and infused NAD+ clears quickly from plasma. This page summarizes what those studies measured rather than judging value or recommending the route; a 2025 review found broader human efficacy still limited ^[15].

When should you inject NAD+?

There is no validated answer: published injectable NAD+ work is confined to wellness-clinic protocols and pilot pharmacokinetics, with no established timing schedule and no FDA-approved indication ^[15]. This page reports the research record, not a dosing instruction, and it does not endorse any protocol or route.

Does NAD IV actually work?

IV NAD+ raises NAD+ metabolites measurably, but plasma NAD+ is largely removed within the first hours and controlled outcome data are minimal. A 2025 review found the broader human efficacy evidence for clinical endpoints still limited ^[15]. No cardiovascular outcome benefit is established for the IV route.